Anzeige
Mehr »
Sonntag, 14.09.2025 - Börsentäglich über 12.000 News
Investment Idee: Einsteigen bevor sich die Schleuse öffnet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
239 Leser
Artikel bewerten:
(1)

Visiongain publishes Pharma Clinical Trial Services Market and Industry Forecast 2020-2030 report

Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Disease

LONDON, Aug. 24, 2020 /PRNewswire/ -- The pharma clinical trials services market is expected to grow at a CAGR of 10% in the first half of the forecast period and be worth $150.15bn by 2030.

Visiongain Logo

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 220-page report you will receive 51 tables and 110 figures- all unavailable elsewhere.

The 220-page Visiongain report provides clear detailed insight into the pharma clinical trial services market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please email contactus@visiongain.com or refer to our website: https://www.visiongain.com/report/pharma-clinical-trial-services-market-and-industry-forecast-2020-2030/download_sampe_div

Report Scope

• Pharma Clinical Trial Services Market forecasts from 2020-2030

• This report breaks down the revenue forecast for pharma clinical trial services market by type of service:
• Early Phase Services
• Late Phase Services
• Other Services

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

• This report breaks down the revenue forecast for pharma clinical trial services market by End-Users:
• Pharma
• Biotech Companies
• Other End-Users

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

• This report breaks down the revenue forecast for pharma clinical trial services market by Therapeutic Area:
• Cancer
• Cardiovascular
• CNS
• Infectious Diseases
• Metabolic Diseases
• Other Diseases

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

• This report provides individual revenue forecasts to 2030 for these regional and national markets:
North America: the US and Rest of North America
Europe: France, Germany, the UK, Spain, Italy, Russia, Central and Eastern Europe, Rest of Europe
Asia-Pacific: China, India, Japan, South Korea, Rest of APAC
• Rest of the World: Latin America, Middle East and Africa, Brazil

Each regional market is further divided by type of service, end-users and therapeutic area.

• Our study discusses factors that drive and restrain the pharma clinical trial services market. This report also provides a STEP analysis.

• This report discusses the leading companies in pharma clinical trial services market:
• Quintiles, Laboratory Corporation of America (LabCorp)
• Pharmaceutical Product Development (PPD)
• Parexel International
• ICON
• INC Research Holdings
• inVentiv Health
• & Other Companies

To request a report overview of this report please email contactus@visiongain.com or refer to our website: https://www.visiongain.com/report/pharma-clinical-trial-services-market-and-industry-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email contactus@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

Almac Group

Ancillare, LP

AstraZeneca

Bayer

Catalent, Inc

Charles River Laboratories

Chiltern International Ltd

CNS Vital Signs

Covance Inc.

Czura Thornton

Forest Pharmaceuticals

GlaxoSmithKline (GSK)

ICON

INC Research Holdings

Institute for Medical Research Management and Biometrics

inVentiv Health

Jasper Clinical Research and Development Inc.

Java Clinical

JCL Bioassay Corporation (part of CMIC Holdings)

KLIFO

Korea National Enterprise for Clinical Trials

LabCorp (Covance Inc.)

Merck KGaA

Novartis

Parexel International Corporation

Pfizer

Pharmaceutical Product Development (PPD), LLC

PRA Health Sciences

Quintiles, Laboratory Corporation of America (LabCorp)

Roche

Sanofi

Syneos Health

Wuxi AppTec Inc

List Organizations Mentioned in the Report

Accreditation of Human Research Protection Programs (AAHRPP)

ACRP: Association of Clinical Research Professionals

European Federation of Pharmaceutical Industries and Associations (EFPIA)

European Medicines Agency (EMA)

International Conference of Harmonisation (ICH)

Japan Pharmaceutical Manufacturers Association (JPMA)

Ministry of Health, Labour and Welfare (MHLW)

Pharmaceutical Research and Manufacturers of America (PhRMA)

Society for Clinical Trials (SCT)

The American Association of Clinical Endocrinologists (AACE)

The Association of Clinical Research Organizations (ACRO)

The Food and Drug Administration (FDA)

The Society of Clinical Research Associates, Inc. (SOCRA)

United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA)

To see a report overview please e-mail contactus@visiongain.com

RELATED REPORTS:

Global Clinical Trial Management System Market Forecast 2020-2030

Clinical Trial Supply and Logistics Market for Pharma 2019-2029

Biopharmaceuticals Contract Manufacturing Market Report 2020-2030

Global IoT Healthcare Market Forecast 2017-2027

Global Contract Research Organisations (CROs) Market Report Forecasts 2020-2030

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

© 2020 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.